The hormone bomb is exploding everywhere in children. But not in Italy
The Italian silence - what are parliamentarians doing? - on gender non-conforming girls treated with hormones is no longer tolerable. How long will we have to wait? Meanwhile, the bubble is breaking out everywhere, from Northern Europe to Australia to the United States, where puberty blockers are starting to be talked about as an unprecedented medical scandal

Share this article

The medicalization of girls and boys who do not conform to gender stereotypes will be the next big medical scandal. While in Italy everything is still shrouded in unbearable silence -how much longer will the health authorities be able to pretend nothing happened?- somewhere else the bubble is bursting.

We have dealt with it several times stop the medicalisation of minors in countries that were pioneers in introducing gender identity, such as Sweden, Finland, Australia. Today we update you on recent developments in the UK and Norway, that go in the direction of set limits to this lucrative branch of the healthcare industry.

AND also in Biden's USA -which instead pushes for the early medicalisation of minors who do not conform to female and male stereotypes - the first lawyers are already appearing (see here, here And here) specialize in medical malpractice lawsuits against gender clinics, accused by former patients (mostly young women) of having sent them to therapies and operations with very serious consequences for their health at an age in which they were unable to understand.


Sajid Javid, current Secretary of State for Health and UK Social Affairs, announced an urgent inquiry into hormone treatments for girls and boys offered by the national health service. The inquiry seeks to ensure that NHS treatment is in the best interests of young patients, and that opposite-sex hormones and other drugs with serious side effects are not prescribed to "vulnerable children".

The Times summarizes Javid's statements thus: “Westminster's health secretary thinks the system is 'failing children' and is planning a review of how health service staff deal with under-18s who question their gender identity” (full article here).

The decision comes following the interim report of Cass Review, a independent evaluation of treatments for minors with gender dysphoria offered by the NHS directed by Dr Hilary Dawn Cass, former President of the Royal College of Paediatrics and Child Health and pediatric disability consultant at St Thomas' Hospital, London.

There interim report highlighted that “there is not enough evidence on the effectiveness of the affirmative model (hormones immediately, without psychological exploration, Ed.)”. It also reads: “Puberty blockers, rather than acting as a 'pause button' to allow children to explore their identity, appear to direct them towards a path of medicalized treatment.”

According to Times, the British Ministry of Health is reportedly preparing legal changes which would give the Cass commission access to data on dysphoric children treated by the National Health Service to see how many later regretted the treatment. The urgent investigation - which will be part of the final report - indicates the desire to immediately change the NHS's approach to the transition of children.


At the beginning of April it came into force in the Sussex region a program that provides compensation to GPs for each prescription of hormones to patients who identify as transgender, promoted by the Sussex Clinical Commissioning Group, the NHS body responsible for health services for the local population.

The program sees GPs in Sussex receive £178 a year for every adult patient they prescribe 'cross hormone therapy'. They will also be able to claim an additional £91 per year to provide an annual check-up to a transgender, non-binary or intersex (TNBI) patient. GPs who want to join the program must follow a two and a half hour online training course on transgender healthcare. Additionally, to receive payments, participating practices will be required to compile a registry of patients considered TNBI.

The Times cites an official document according to which the purpose of the program would be “to provide 'interim support' to patients on the hospital waiting list gender clinics and 'improving access' to hormone therapy. The document adds that any decision to start hormone therapy is 'at the discretion of the individual family doctor'” (full article HERE).

However they arrived criticism from family doctors and also from some trans rights activists, concerned that the program could lead doctors to provide drugs without adequate psychological support for patients and place an additional burden on GPs.

The Times he heard Debbie Hayton, trans rights activist who made the transition in 2012. Hayton questioned the level of psychological support provided by the programme. “When I transitioned I talked to a therapist an hour a week for months,” she said. “It was what I needed to understand myself. An annual check-up is but a pale shadow in comparison.”

Furthermore, the Times reports the words of Zara Aziz, a GP in Bristol. “It seems like… this [task] has been passed on to GPs with a training package and off they go,” the doctor said, hinting at concerns about the burden of responsibility that accompanies prescribing hormones. The latest judgment rendered in Keira Bell's case (see here) has in fact clarified that the responsibility for evaluating the patient falls on the doctor and not on the judge or other figure.

With this program, in Sussex civil and criminal liability will no longer fall on the "specialists" of gender clinics, but on family doctors. And it is understandable that the latter want to protect themselves, given the non-negligible increase in cases of detransition -i.e. patients who heal from gender dysphoria and return to feeling good in their bodies as women or men.


In Norway they have been published new national guidelines on the treatment of minors with gender dysphoria, that they put end the liberalization of hormones and puberty blockers for minors, establishing that they can only be prescribed after careful testing psychological evaluation of the patient in centers specialized in the treatment of gender dysphoria.

The country is fully included among the "Pioneer countries" of gender identity, having already introduced the self-ID - gender self-determination model in 2016, without a medical evaluation and with a very simple bureaucratic process. “Norwegians can now legally change sex with the click of a mouse,” he headlined at the time Associated Press.

Norwegian law allows children aged 6 and over to change the sex on their documents according to their "gender identity".

However, until 2020 the medicalisation of minors occurred more severely than the change of registered sex: drugs could only be legally prescribed by the National Clinic for Transsexualism (NBTS) at the Rikshospitalet (National Hospital) in Oslo.

The 2020 guidelines, heavily influenced by LGBTQ interest groups, aimed to make it “easier to obtain gender confirmatory treatment, among other things by establishing more offers around Norway”: they authorized the “transgender medicine” departments of local hospitals, which until then had only provided psychiatric evaluations and therapies, to prescribe hormones and perform surgical operations as a treatment for gender dysphoria. type.

"They have liberalized access to a treatment that is irreversible and has important consequences, without having an adequate knowledge base. This in itself is unjustifiable,” said Pål Surén, pediatrician at the Public Health Institute (FHI), joining the criticisms of the Rikshospitalet and the Norwegian Association for Child and Adolescent Psychiatry.

After the publication of the new guidelines, the debate continues between the side of caution and that of the 'affirmative' approach, represented by the Health Clinic for Gender and Sexuality (HKS), the main "competitor" of the Rikshospitalet for transgender healthcare ( see this item).

Even in Norway, therefore, it is a question of placing limits on the profitable transition healthcare industry, especially in cases where children and adolescents pay the price.


Meanwhile in the USA the war continues between the Biden administration, which supports trans-affirmative pharmacological treatments for minors, and the Republican governors of some states.

The The Justice Department has attacked an Alabama law that makes it a crime for doctors to treat transgender people under the age of 19 with puberty blockers and hormones. The law should come into force on May 8 (the news here).

The department had already sent a letter to all 50 state attorneys general warning that preventing transgender and nonbinary youth from receiving gender-affirming care could be a violation of federal constitutional protections. But Alabama Republicans who supported the law said it is necessary to protect children.

Alabama Attorney General Steve Marshall said “the Biden administration has chosen to prioritize left-wing politics at the expense of Alabama's children. As we will demonstrate, the Justice Department's claim that these treatments are 'medically necessary' is one ideology-based disinformation. Science and common sense are on Alabama's side. We will win this battle to protect our children."

Maria Celeste

Share this article
Scroll to Top